C-Ray Therapeutics Secures AAALAC Accreditation, Strengthening Global Radiopharma Platform

New updates have been reported about C Ray Therapeutics.

C-Ray Therapeutics has obtained Full Accreditation from AAALAC International for its Chengdu operations, a credential that aligns its preclinical animal research standards with leading global benchmarks and directly supports Western-grade regulatory submissions. The accreditation covers the company’s 28,000-square-meter integrated radiopharmaceutical facility, where AAALAC-compliant preclinical services are combined with cGMP manufacturing under China’s Class A Radiation Safety License, allowing work with more than 30 radioisotopes, including complex alpha emitters such as Actinium-225.

Management positions this accreditation as a strategic lever for C-Ray’s CRDMO business, enabling biotech clients to run preclinical programs in China with data quality and ethics suitable for Western regulators while using the company’s investigator-initiated trial framework to compress first-in-human timelines to roughly six to nine months versus multi‑year traditional pathways. C-Ray reports delivery of over 70 radiopharmaceutical projects to date, including 50 preclinical and molecular imaging assignments and 24 CDMO mandates, with five programs supported through IND or IND-enabling stages, 16 IITs initiated, and three clinical supply programs, two of which have advanced to Phase III trials.

The AAALAC milestone comes as C-Ray expands its international reach and seeks to position its China-based platform as a cost- and speed-advantaged alternative for global radiopharma development without compromising compliance or ethics. Executives emphasize that the new accreditation addresses a key hurdle for Western partners that require rigorous animal welfare and data integrity while looking to arbitrage China’s operating efficiencies. With more than $187 million raised so far, C-Ray plans to continue investing in infrastructure, isotope supply chain partnerships, and regulatory capabilities to deepen its role as an end-to-end provider from target validation through commercial-scale manufacturing in the rapidly growing radiopharmaceutical sector.